Loading...
A phase II window of opportunity study of preoperative olaparib (O) with cisplatin (C) or durvalumab (D) or olaparib alone in in patients with operable squamous cell head and neck carcinoma (HNSCC) (OPHELIA)
Psyrri, A Economopoulou, P Kotsantis, I Koutsodontis, G Cheila, M Papaxoinis, Georgios Pectasides, DG Fountzilas, G Krikoni, L Souliotis, V
Psyrri, A
Economopoulou, P
Kotsantis, I
Koutsodontis, G
Cheila, M
Papaxoinis, Georgios
Pectasides, DG
Fountzilas, G
Krikoni, L
Souliotis, V
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 105.98 KB
Keywords
Type
Meetings and Proceedings
Citation
Psyrri A, Economopoulou P, Kotsantis I, Koutsodontis G, Cheila M, Papaxoinis G, et al. 1045O A phase II window of opportunity study of preoperative olaparib (O) with cisplatin (C) or durvalumab (D) or olaparib alone in in patients with operable squamous cell head and neck carcinoma (HNSCC) (OPHELIA). Annals of Oncology. 2018;29(suppl_8).